All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @codejorge on TikTok · 43s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @codejorge's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Kpv won't make you super fucking sick. Yes the fucking inflammation peptide
  2. 0:05That's supposed to fucking be beneficial for you and your skin and your gut health
  3. 0:09That shit is gonna make you sick if you do too much if you do over 700 micrograms and one dose
  4. 0:16I'm telling you your fucking immune system is gonna be fucked for at least a day or two and you are gonna feel sick all
  5. 0:22Of the next day
  6. 0:23Especially if you're working with kids or you're working in hospitals or you're just around like a lot of dirty shit
  7. 0:29Like you go to the gym a lot you will get fucking sick and I can tell you that because I literally did that shit last night
  8. 0:34And I woke up fucking insanely sick. So if you're taking Kpv
  9. 0:39Do a small dose anti-trade up

KPV peptide: what 'overdoing it' actually means for your gut

codejorge

TikTok creator

8.5K viewsWatch on TikTok

Quick answer

KPV (Lys-Pro-Val) is a C-terminal tripeptide of alpha-MSH studied primarily in rodent models of intestinal inflammation, where it appears to reduce NF-kB-mediated signaling. No peer-reviewed human clinical trials have established safe dosing ranges, therapeutic windows, or dose-dependent adverse effect profiles for KPV. The creator's reported symptoms following a self-administered high dose are anecdotal and cannot be attributed to a specific immunosuppressive mechanism without controlled data.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For KPV peptide: what 'overdoing it' actually means for your gut, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

KPV peptide: what 'overdoing it' actually means for your gut is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "KPV peptide: what 'overdoing it' actually means for your gut" from codejorge. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: KPV (Lys-Pro-Val) is a C-terminal tripeptide of alpha-MSH studied primarily in rodent models of intestinal inflammation, where it appears to reduce NF-kB-mediated signaling.

The reason this review is not generic is the source wording and the canonical claim label "peptides overdoing kpv kpv peps fyp." In this clip, the useful excerpt is: "Kpv won't make you super fucking sick." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against SCENESSE (afamelanotide implant) FDA Prescribing Information (2019), Afamelanotide for Erythropoietic Protoporphyria (2015), and Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (2012), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The 700 microgram threshold mentioned in the video has no peer-reviewed citation.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

KPV (Lys-Pro-Val) is a C-terminal tripeptide of alpha-MSH studied primarily in rodent models of intestinal inflammation, where it appears to reduce NF-kB-mediated signaling.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • KPV (Lys-Pro-Val) is a C-terminal tripeptide of alpha-MSH studied primarily in rodent models of intestinal inflammation, where it appears to reduce NF-kB-mediated signaling. No peer-reviewed human clinical trials have established safe dosing ranges, therapeutic windows, or dose-dependent adverse effect profiles for KPV. The creator's reported symptoms following a self-administered high dose are anecdotal and cannot be attributed to a specific immunosuppressive mechanism without controlled data.
  • KPV has shown anti-inflammatory effects in rodent IBD models (Dalmasso et al., 2008; Kannengiesser et al., 2008) but has no FDA-approved indication and no published human clinical dosing data.
  • The 700 microgram threshold mentioned in the video has no peer-reviewed citation. It is community-derived and should not be treated as an established safety cutoff.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • KPV has shown anti-inflammatory effects in rodent IBD models (Dalmasso et al., 2008; Kannengiesser et al., 2008) but has no FDA-approved indication and no published human clinical dosing data.
  • The 700 microgram threshold mentioned in the video has no peer-reviewed citation. It is community-derived and should not be treated as an established safety cutoff.
  • Feeling sick after a large dose of an unregulated compounded peptide could reflect impurities, injection site reactions, or coincidental illness, not necessarily a pharmacological immune effect.
  • Alpha-MSH and its fragments act on melanocortin receptors involved in immune modulation, so the general idea that large doses could affect immune signaling is biologically plausible, but it remains unproven in human dose-response studies.
  • Anyone self-administering peptides outside a supervised clinical context is using compounds with no established human safety profile, no standardized purity requirements, and no regulatory oversight of dosing.
  • The creator's closing advice to start low and titrate up is the one piece of this video with practical merit, though it does not make the surrounding claims more accurate.
  • FormBlends does not endorse self-directed peptide use based on social media anecdotes. Any peptide therapy should be discussed with a licensed clinician who can evaluate individual risk factors.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @codejorge actually say?

He said taking over 700 micrograms of KPV in a single dose will "fuck your immune system for at least a day or two" and make you feel sick the next day, especially if you're exposed to a lot of pathogens, like at a gym, hospital, or around kids. His evidence: he did it the night before and woke up feeling terrible. He closes with a practical note: start small and titrate up.

To be clear, this is an n=1 anecdote dressed up as a dosing warning. He's not citing literature. He's describing what happened to him personally after what sounds like a significant one-time dose of a peptide that has almost no peer-reviewed human dosing data behind it. That context matters a lot before we evaluate whether his conclusion holds up.

Does the science back this up?

Partially, but not for the reason he thinks. KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). The existing research, which is largely preclinical, shows it has anti-inflammatory properties, particularly in gut tissue. The idea that overdoing an anti-inflammatory compound could temporarily blunt immune defense is biologically plausible, but the specific mechanism he's describing is not well-established in humans at any dose.

Most of the published KPV work involves animal models of inflammatory bowel disease. Dalmasso et al. (2008, Journal of Molecular Medicine) showed KPV could reduce intestinal inflammation in colitis models by inhibiting NF-kB signaling. Kannengiesser et al. (2008, Peptides) confirmed oral KPV reduced colitis severity in mice. Neither study addressed immune suppression at high doses in humans. The 700 microgram threshold he mentions has no citation behind it. It appears to come from community experience on peptide forums, not clinical data.

What did they get wrong (or right)?

He got the directional logic roughly right and almost everything else wrong in the specifics. Yes, an anti-inflammatory peptide acting on immune signaling pathways could theoretically reduce your acute immune responsiveness if dosed high enough. That's not a crazy inference. But calling it a confirmed effect, attaching a specific number like "700 micrograms," and explaining it as your immune system getting "fucked" is a significant oversimplification.

What's more likely happening in his case: he was already exposed to something before the dose, or the systemic inflammatory response he was trying to modulate backfired in a way that had nothing to do with immune suppression specifically. Feeling sick after a large peptide dose could also reflect impurities in unregulated compounded peptides, injection site reactions, or a coincidental viral exposure. His confidence in the 700 microgram cutoff is not supported by any published dose-response study in humans. He presents one bad night as a pharmacological rule.

What should you actually know?

KPV is not FDA-approved for any indication. It is not a proven treatment for gut disease or skin conditions in humans. The anti-inflammatory effects observed in animal models are real, but translating preclinical data to human dosing protocols is where things get speculative fast.

The "start small and titrate up" advice he ends with is genuinely sound harm-reduction logic for any investigational compound. That part deserves credit. But the rest of the framing, that KPV is reliably beneficial for gut health and skin and you just need to watch your dose, skips over the fact that there are no established safe or effective doses in human clinical trials. Anyone using KPV outside a supervised research context is working without a safety net. One person's bad night on TikTok is not a substitute for a pharmacokinetic study.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

codejorge · TikTok creator

8.5K views on this video

Overdoing KPV #kpv #peps #fyp

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about kpv has shown anti-inflammatory effects in rodent ibd models (dalmasso?

KPV has shown anti-inflammatory effects in rodent IBD models (Dalmasso et al., 2008; Kannengiesser et al., 2008) but has no FDA-approved indication and no published human clinical dosing data.

What does the video say about the 700 microgram threshold mentioned in the video has no?

The 700 microgram threshold mentioned in the video has no peer-reviewed citation. It is community-derived and should not be treated as an established safety cutoff.

What does the video say about feeling sick after a large dose of an unregulated compounded?

Feeling sick after a large dose of an unregulated compounded peptide could reflect impurities, injection site reactions, or coincidental illness, not necessarily a pharmacological immune effect.

What does the video say about alpha-msh?

Alpha-MSH and its fragments act on melanocortin receptors involved in immune modulation, so the general idea that large doses could affect immune signaling is biologically plausible, but it remains unproven in human dose-response studies.

What does the video say about anyone self-administering peptides outside a supervised clinical context?

Anyone self-administering peptides outside a supervised clinical context is using compounds with no established human safety profile, no standardized purity requirements, and no regulatory oversight of dosing.

What does the video say about the creator's closing advice to start low?

The creator's closing advice to start low and titrate up is the one piece of this video with practical merit, though it does not make the surrounding claims more accurate.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by codejorge, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.